These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3966916)

  • 1. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
    Boobis AR; Murray S; Hampden CE; Davies DS
    Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
    Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
    Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
    Prueksaritanont T; Dwyer LM; Cribb AE
    Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
    Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
    J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attempts to phenotype human liver samples in vitro for debrisoquine 4-hydroxylase activity.
    Boobis AR; Hampden CE; Murray S; Beaune P; Davies DS
    Br J Clin Pharmacol; 1985 Jun; 19(6):721-9. PubMed ID: 4027115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
    Dayer P; Kronbach T; Eichelbaum M; Meyer UA
    Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors.
    Boobis AR; Seddon CE; Davies DS
    Biochem Pharmacol; 1986 Sep; 35(17):2961-5. PubMed ID: 3741485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.
    Distlerath LM; Reilly PE; Martin MV; Davis GG; Wilkinson GR; Guengerich FP
    J Biol Chem; 1985 Jul; 260(15):9057-67. PubMed ID: 4019462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
    Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
    Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.
    Minder EI; Meier PJ; Müller HK; Minder C; Meyer UA
    Eur J Clin Invest; 1984 Jun; 14(3):184-9. PubMed ID: 6147254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
    Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
    FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catalytic specificity of CYP2D isoforms in rat and human.
    Hiroi T; Chow T; Imaoka S; Funae Y
    Drug Metab Dispos; 2002 Sep; 30(9):970-6. PubMed ID: 12167561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.
    Wolff T; Distlerath LM; Worthington MT; Groopman JD; Hammons GJ; Kadlubar FF; Prough RA; Martin MV; Guengerich FP
    Cancer Res; 1985 May; 45(5):2116-22. PubMed ID: 3921236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
    Zanger UM; Vilbois F; Hardwick JP; Meyer UA
    Biochemistry; 1988 Jul; 27(15):5447-54. PubMed ID: 3052575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.
    Kronbach T
    Methods Enzymol; 1991; 206():509-17. PubMed ID: 1686064
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
    Mankowski DC
    Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s.
    Narimatsu S; Takemi C; Kuramoto S; Tsuzuki D; Hichiya H; Tamagake K; Yamamoto S
    Chirality; 2003 May; 15(4):333-9. PubMed ID: 12666241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.